Jane Davies: Difference between revisions
added Category:British paediatricians using HotCat |
Duncan.Hull (talk | contribs) |
||
Line 1: | Line 1: | ||
{{Infobox scientist |
{{Infobox scientist |
||
| name = Jane Davies |
| name = Jane Davies |
||
| birth_name = Jane C. Davies |
|||
| birth_date = {{birth year and age|1963}}{{fact}} |
|||
| fields = [[Cystic fibrosis]]<br>[[Gene therapy]]<ref name=gs/> |
|||
| website = {{URL|imperial.ac.uk/people/j.c.davies}} |
|||
| alma_mater = [[University of Dundee]] <br> [[Royal Brompton Hospital]] |
| alma_mater = [[University of Dundee]] <br> [[Royal Brompton Hospital]] |
||
| workplaces = [[Imperial College London]] |
| workplaces = [[Imperial College London]] |
||
}} |
}} |
||
'''Jane Davies''' (born November 9, 1963) is a British physician who is Professor of [[Paediatric]] [[Respirology]] at the [[National Heart and Lung Institute]]. She is an Honorary Consultant at the [[Royal Brompton and Harefield NHS Foundation Trust]]. |
'''Jane C. Davies''' (born November 9, 1963){{fact}} is a British physician who is Professor of [[Paediatric]] [[Respirology]] at the [[National Heart and Lung Institute]].<ref name=gs>{{Google scholar id}}</ref><ref name=scopus>{{Scopus id}}</ref><ref name=epmc>{{EuropePMC|ORCID=0000-0003-3506-1199}}</ref> She is an Honorary Consultant at the [[Royal Brompton and Harefield NHS Foundation Trust]]. |
||
== Early life and education == |
== Early life and education == |
||
Davies studied medicine at the [[University of Dundee]].<ref name=":0">{{Cite web|url=https://www.imperial.ac.uk/people/j.c.davies|title=Home - Professor Jane Davies|website= |
Davies studied medicine at the [[University of Dundee]].<ref name=":0">{{Cite web|url=https://www.imperial.ac.uk/people/j.c.davies|title=Home - Professor Jane Davies|website=imperial.ac.uk|access-date=2019-02-25}}</ref> She graduated in 1987, and began [[paediatric]] training in London.<ref name=":0" /> She began to work at the [[Royal Brompton Hospital]] on [[Cystic fibrosis|cystic fibrosis]].<ref name=":0" /> She earned her MD on [[Host-pathogen interaction|host-pathogen interactions]] under the supervision of Andrew Bush and Eric Alton. She looked at the pathogensis of ''[[Pseudomonas aeruginosa]]''.<ref name=":0" /> |
||
== Career == |
== Career and research== |
||
Davies joined the [[National Heart and Lung Institute]] in 1999, where she has specialised in [[Cystic fibrosis|cystic fibrosis]].<ref>{{Cite journal|last=Bush|first=Andrew|last2=Alton|first2=Eric W. F. W.|last3=Davies|first3=Jane C.|date=2007 |
Davies joined the [[National Heart and Lung Institute]] in 1999, where she has specialised in [[Cystic fibrosis|cystic fibrosis]].<ref>{{Cite journal|last=Bush|first=Andrew|last2=Alton|first2=Eric W. F. W.|last3=Davies|first3=Jane C.|date=2007|title=Cystic fibrosis|pmc=2137053|journal=BMJ|language=en|volume=335|issue=7632|pages=1255–1259|doi=10.1136/bmj.39391.713229.AD|issn=0959-8138|pmid=18079549}}</ref> Davies has been involved with the UK CF Gene Therapy Consortium since it was established in 2002.<ref name=":0" /> Davies worked on the development of [[Cystic fibrosis transmembrane conductance regulator]] (CFTR) [[gene therapy]].<ref name=gs/><ref name="RamseyDavies2011">{{cite journal|last1=Ramsey|first1=Bonnie W.|last2=Davies|first2=Jane|last3=McElvaney|first3=N. Gerard|last4=Tullis|first4=Elizabeth|last5=Bell|first5=Scott C.|last6=Dřevínek|first6=Pavel|last7=Griese|first7=Matthias|last8=McKone|first8=Edward F.|last9=Wainwright|first9=Claire E.|last10=Konstan|first10=Michael W.|last11=Moss|first11=Richard|last12=Ratjen|first12=Felix|last13=Sermet-Gaudelus|first13=Isabelle|last14=Rowe|first14=Steven M.|last15=Dong|first15=Qunming|last16=Rodriguez|first16=Sally|last17=Yen|first17=Karl|last18=Ordoñez|first18=Claudia|last19=Elborn|first19=J. Stuart|title=A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation|journal=New England Journal of Medicine|volume=365|issue=18|year=2011|pages=1663–1672|issn=0028-4793|doi=10.1056/NEJMoa1105185|pmid=22047557 |pmc=3230303 }}</ref> She conducts [[Bronchoscopy|bronchoscopic]] assays and [[electrophysiological]] measurements.<ref name=":0" /> She was made a Reader in 2009 and a Professor in 2013.{{cn|date=February 2019}} Davies investigates [[Cystic fibrosis|cystic fibrosis]]. She was involved with a major UK trial of gene therapy for cystic fibrosis.<ref>{{Cite web|url=https://www.thenakedscientists.com/articles/interviews/prof-jane-davies-cf-gene-therapy|title=Prof Jane Davies - CF gene therapy {{!}} Interviews {{!}} Naked Scientists|website=thenakedscientists.com|access-date=2019-02-25}}</ref> |
||
Davies leads the Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis at [[Imperial College London]], one of few centres supported by the [[Cystic Fibrosis Trust]].<ref>{{Cite web|url=http://www.imperial.ac.uk/medicine/departments/nhli/research/centres-and-initiatives/strategic-research-centre-pseudomonas-infection/|title=Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis|website=Imperial College London|language=en-GB|access-date=2019-02-25}}</ref> The centre looks to identify new ways to detect [[Pseudomonas aeruginosa|pseudomonas aeruginosa]].<ref>{{Cite web|url=https://www.cysticfibrosis.org.uk/en/the%20work%20we%20do/research/research%20we%20are%20funding/strategic%20research%20centres/src%2014%20davies|title=Strategic Research Centre: Personalised approach to Pseudomonas aeruginosa (PAPA)|website= |
Davies leads the Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis at [[Imperial College London]], one of few centres supported by the [[Cystic Fibrosis Trust]].<ref>{{Cite web|url=http://www.imperial.ac.uk/medicine/departments/nhli/research/centres-and-initiatives/strategic-research-centre-pseudomonas-infection/|title=Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis|website=Imperial College London|language=en-GB|access-date=2019-02-25}}</ref> The centre looks to identify new ways to detect [[Pseudomonas aeruginosa|pseudomonas aeruginosa]].<ref>{{Cite web|url=https://www.cysticfibrosis.org.uk/en/the%20work%20we%20do/research/research%20we%20are%20funding/strategic%20research%20centres/src%2014%20davies|title=Strategic Research Centre: Personalised approach to Pseudomonas aeruginosa (PAPA)|website=cysticfibrosis.org.uk|language=en|access-date=2019-02-25}}</ref><ref>{{Citation|last=Imperial College London|title=Detecting and treating infection in cystic fibrosis|date=2017-07-28|url=https://www.youtube.com/watch?v=RHhH5_ZMzfI|access-date=2019-02-25}}</ref> Davies is part of the European CF Society Clinical Trials Network.<ref name=":0" /><ref>{{Cite web|url=http://www.paediatricrespiratory.com/prof-jane-davies|title=Prof Jane Davies|website=Paediatric Respiratory Conference|language=en-US|access-date=2019-02-25}}</ref><ref>{{Cite web|url=http://www.cfcourse-online.co.uk/dr-jane-davies-bio|title=cfcourse|website=cfcourse-online.co.uk|access-date=2019-02-25}}</ref> She was involved in the design of the clinical trial, as well as validation of outcome measures.<ref>{{Cite web|url=http://justgenetherapy.org/about-us/london.htm|title=Just Gene Therapy: About us - Imperial College London|website=justgenetherapy.org|access-date=2019-02-25}}</ref><ref>{{Cite web|url=http://enterprisetherapeutics.com/about-us/advisory-board/dr-jane-davies-mb-chb/|title=Dr Jane Davies MB Chb|website=Enterprise Therapeutics|language=en-US|access-date=2019-02-25}}</ref> She works on the use of nasal potential difference to diagnose atypical [[Cystic fibrosis|cystic fibrosis]].<ref name=":0" /><ref>{{Cite web|url=https://www.cysticfibrosis.org.uk/en/the%20work%20we%20do/research/research%20we%20are%20funding/strategic%20research%20centres/src%201%20pseudomonas|title=Strategic Research Centre: Pseudomonas|website=cysticfibrosis.org.uk|language=en|access-date=2019-02-25}}</ref> She was awarded a £2.8 million research grant from the [[Wellcome Trust]] to optimise the [[lentiviral vector]] for [[gene therapy]]. |
||
=== |
=== Publications === |
||
Davies publications<ref name=gs/><ref name=scopus/><ref name=epmc/> include: |
|||
* {{cite chapter|chapter=Current and Novel Antimicrobial Approaches|first=Jane|last=Davies|url=http://worldcat.org/oclc/728412484|title=Cystic Fibrosis in the 21st Century|editor=Bush, A.|place=London|date=2006|publisher=S. Karger|isbn=9783318012408|oclc=728412484}} |
* {{cite chapter|chapter=Current and Novel Antimicrobial Approaches|first=Jane|last=Davies|url=http://worldcat.org/oclc/728412484|title=Cystic Fibrosis in the 21st Century|editor=Bush, A.|place=London|date=2006|publisher=S. Karger|isbn=9783318012408|oclc=728412484}} |
||
* {{cite chapter|title=Cystic Fibrosis in the 21st Century|url=https://www.worldcat.org/oclc/71126311|chapter=CF Modifier Genes|date=2006|publisher=Karger|editor=Bush, Andrew|isbn=1423796802|location=Basel|oclc=71126311|first1=U.|last1=Greisenbach|first2=E.W.F.W.|last2=Alton|first3=J.C.|last3=Davies}} |
* {{cite chapter|title=Cystic Fibrosis in the 21st Century|url=https://www.worldcat.org/oclc/71126311|chapter=CF Modifier Genes|date=2006|publisher=Karger|editor=Bush, Andrew|isbn=1423796802|location=Basel|oclc=71126311|first1=U.|last1=Greisenbach|first2=E.W.F.W.|last2=Alton|first3=J.C.|last3=Davies}} |
||
* 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 1 Airways & Infection |
* 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 1 Airways & Infection{{ISBN missing}} |
||
* 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 2 Parenchymal Disease |
* 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 2 Parenchymal Disease{{ISBN missing}} |
||
* {{Cite journal|last=Alton|first=Eric W|last2=Davies|first2=Jane C|last3=Griesenbach|first3=Uta|date=2013|title=Current & emerging pharmaceutical treatments for cystic fibrosis lung disease |
* {{Cite journal|last=Alton|first=Eric W|last2=Davies|first2=Jane C|last3=Griesenbach|first3=Uta|date=2013|title=Current & emerging pharmaceutical treatments for cystic fibrosis lung disease|journal=Current & Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung Disease|volume=|pages=2–4|doi=10.2217/ebo.13.170|via=}} |
||
== References == |
== References == |
||
{{reflist}} |
|||
{{Authority control}} |
|||
[[Category:1963 births]] |
[[Category:1963 births]] |
||
[[Category:British paediatricians]] |
[[Category:British paediatricians]] |
||
{{DEFAULTSORT: Davies, Jane}} |
Revision as of 11:46, 26 February 2019
Jane Davies | |
---|---|
Born | Jane C. Davies 1963 (age 60–61)[citation needed] |
Alma mater | University of Dundee Royal Brompton Hospital |
Scientific career | |
Fields | Cystic fibrosis Gene therapy[1] |
Institutions | Imperial College London |
Website | imperial |
Jane C. Davies (born November 9, 1963)[citation needed] is a British physician who is Professor of Paediatric Respirology at the National Heart and Lung Institute.[1][2][3] She is an Honorary Consultant at the Royal Brompton and Harefield NHS Foundation Trust.
Early life and education
Davies studied medicine at the University of Dundee.[4] She graduated in 1987, and began paediatric training in London.[4] She began to work at the Royal Brompton Hospital on cystic fibrosis.[4] She earned her MD on host-pathogen interactions under the supervision of Andrew Bush and Eric Alton. She looked at the pathogensis of Pseudomonas aeruginosa.[4]
Career and research
Davies joined the National Heart and Lung Institute in 1999, where she has specialised in cystic fibrosis.[5] Davies has been involved with the UK CF Gene Therapy Consortium since it was established in 2002.[4] Davies worked on the development of Cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy.[1][6] She conducts bronchoscopic assays and electrophysiological measurements.[4] She was made a Reader in 2009 and a Professor in 2013.[citation needed] Davies investigates cystic fibrosis. She was involved with a major UK trial of gene therapy for cystic fibrosis.[7]
Davies leads the Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis at Imperial College London, one of few centres supported by the Cystic Fibrosis Trust.[8] The centre looks to identify new ways to detect pseudomonas aeruginosa.[9][10] Davies is part of the European CF Society Clinical Trials Network.[4][11][12] She was involved in the design of the clinical trial, as well as validation of outcome measures.[13][14] She works on the use of nasal potential difference to diagnose atypical cystic fibrosis.[4][15] She was awarded a £2.8 million research grant from the Wellcome Trust to optimise the lentiviral vector for gene therapy.
Publications
Davies publications[1][2][3] include:
- Davies, Jane (2006). "Current and Novel Antimicrobial Approaches". In Bush, A. (ed.). Cystic Fibrosis in the 21st Century. London: S. Karger. ISBN 9783318012408. OCLC 728412484.
- Greisenbach, U.; Alton, E.W.F.W.; Davies, J.C. (2006). "CF Modifier Genes". In Bush, Andrew (ed.). Cystic Fibrosis in the 21st Century. Basel: Karger. ISBN 1423796802. OCLC 71126311.
- 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 1 Airways & Infection[ISBN missing]
- 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 2 Parenchymal Disease[ISBN missing]
- Alton, Eric W; Davies, Jane C; Griesenbach, Uta (2013). "Current & emerging pharmaceutical treatments for cystic fibrosis lung disease". Current & Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung Disease: 2–4. doi:10.2217/ebo.13.170.
References
- ^ a b c d Jane Davies publications indexed by Google Scholar
- ^ a b Jane Davies publications indexed by the Scopus bibliographic database. (subscription required)
- ^ a b Jane Davies publications from Europe PubMed Central
- ^ a b c d e f g h "Home - Professor Jane Davies". imperial.ac.uk. Retrieved 2019-02-25.
- ^ Bush, Andrew; Alton, Eric W. F. W.; Davies, Jane C. (2007). "Cystic fibrosis". BMJ. 335 (7632): 1255–1259. doi:10.1136/bmj.39391.713229.AD. ISSN 0959-8138. PMC 2137053. PMID 18079549.
- ^ Ramsey, Bonnie W.; Davies, Jane; McElvaney, N. Gerard; Tullis, Elizabeth; Bell, Scott C.; Dřevínek, Pavel; Griese, Matthias; McKone, Edward F.; Wainwright, Claire E.; Konstan, Michael W.; Moss, Richard; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Rowe, Steven M.; Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordoñez, Claudia; Elborn, J. Stuart (2011). "A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation". New England Journal of Medicine. 365 (18): 1663–1672. doi:10.1056/NEJMoa1105185. ISSN 0028-4793. PMC 3230303. PMID 22047557.
- ^ "Prof Jane Davies - CF gene therapy | Interviews | Naked Scientists". thenakedscientists.com. Retrieved 2019-02-25.
- ^ "Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis". Imperial College London. Retrieved 2019-02-25.
- ^ "Strategic Research Centre: Personalised approach to Pseudomonas aeruginosa (PAPA)". cysticfibrosis.org.uk. Retrieved 2019-02-25.
- ^ Imperial College London (2017-07-28), Detecting and treating infection in cystic fibrosis, retrieved 2019-02-25
- ^ "Prof Jane Davies". Paediatric Respiratory Conference. Retrieved 2019-02-25.
- ^ "cfcourse". cfcourse-online.co.uk. Retrieved 2019-02-25.
- ^ "Just Gene Therapy: About us - Imperial College London". justgenetherapy.org. Retrieved 2019-02-25.
- ^ "Dr Jane Davies MB Chb". Enterprise Therapeutics. Retrieved 2019-02-25.
- ^ "Strategic Research Centre: Pseudomonas". cysticfibrosis.org.uk. Retrieved 2019-02-25.